Actavis hit with suit over recalled Digitek

Maybe not faster than a speeding bullet, but close. Lawyers already are filing a class-action lawsuit against Iceland's Actavis over the recalled heart drug Digitek, which was just pulled off the market two weeks ago. (The suit also names Mylan, which distributed the meds.)

The generics maker pulled the drug because some batches may have included tablets that were twice the normal strength. Plaintiffs are alleging injury and asking for damages and medical monitoring in case of future health problems. At the time of the recall, Actavis said the stronger tablets might cause toxicity in renal-failure patients.

- see the item at the WSJ Health Blog

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.